Can direct to consumer access help Vanda scale NEREUS beyond niche travel use?
Motion sickness finally has a new prescription drug. Vanda’s test is whether NEREUS can move beyond travel novelty into real demand.
Pharma & Biotech
Features & Analysis
Why Sixty Degrees Pharmaceuticals is betting on retail channels for tafenoquine adoption
Tafenoquine’s retail debut via GoodRx marks a shift in malaria prevention access. Find out what this means for U.S. travel medicine strategy.
Medical Devices & Diagnostics
Why 60 Degrees Pharmaceuticals is betting on Runway Health to reshape malaria prevention access
Discover how 60 Degrees Pharmaceuticals is using telehealth to expand ARAKODA access and what this shift means for malaria prevention strategy.